U.S. Markets closed

Colgate-Palmolive Beats On Q4; Notes Margin Pressure

  • Colgate-Palmolive Co (NYSE: CL) reported fourth-quarter FY22 sales growth of 5% year-on-year to $4.629 billion, beating the consensus of $4.59 billion.

  • Organic sales increased by 8.5%. Total Oral, Personal, and Home Care net sales increased by 1.4% to $3.6 billion.

  • Non-GAAP EPS of $0.77 beat the analyst consensus of $0.76.

  • During Q4, the company took a non-cash, after-tax charge of $620 million to adjust the carrying values of goodwill and intangible assets related to the Filorga skin health business.

  • Gross profit was $2.57 billion, while the margin contracted 250 basis points to 55.6%.

  • Selling, general and administrative expenses rose 2.1% to $1.6 billion.

  • Operating margin contracted 390 basis points to 4.4%, and operating income for the quarter fell 44.6% to $202 million.

  • The company held $775 million in cash and equivalents as of Dec. 31, 2022. Net cash provided by operations was $2.55 billion for 2022.

  • "We are also strengthening and scaling our digital, data analytics, innovation and other capabilities across the company," said Chairman, President, and CEO Noel Wallace.

  • Outlook: Colgate sees FY23 organic sales growth of 2% - 5%.

  • The company expects organic sales growth to be towards the high end of its long-term targeted range of 3% to 5%.

  • On a non-GAAP basis, the company expects gross profit margin expansion, increased advertising investment, and low to mid-single-digit EPS growth.

  • Price Action: CL shares are trading lower by 3.22% at $73.10 in premarket on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.